Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$183.06K$183.06Kno prior Q3 2016 on file Net Income-$3.99M-$3.99MN/M vs Q3 2016 EPS Diluted-$0.39-$0.39N/M vs Q3 2016 Operating Income-$3,989,510N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2179.3%
Net margin-2177.1%
ended Sep 30, 2017 · filed Nov 14, 2017 · 45 d after period end